Focus Partners Advisor Solutions LLC Grows Holdings in Medpace Holdings, Inc. $MEDP

Focus Partners Advisor Solutions LLC boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 229.7% in the third quarter, HoldingsChannel reports. The fund owned 4,487 shares of the company’s stock after acquiring an additional 3,126 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Medpace were worth $2,307,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Quent Capital LLC bought a new position in shares of Medpace during the third quarter valued at approximately $25,000. Optiver Holding B.V. purchased a new stake in shares of Medpace in the 3rd quarter worth approximately $27,000. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Employees Retirement System of Texas purchased a new position in Medpace during the second quarter valued at $36,000. Finally, Root Financial Partners LLC purchased a new position in Medpace during the third quarter valued at $38,000. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 0.1%

Shares of NASDAQ MEDP opened at $465.86 on Thursday. The firm’s 50-day moving average price is $537.93 and its 200-day moving average price is $538.85. The company has a market cap of $13.22 billion, a PE ratio of 30.45, a PEG ratio of 2.23 and a beta of 1.44. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. During the same period in the previous year, the company earned $3.67 earnings per share. The firm’s quarterly revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on MEDP. Zacks Research cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Barclays cut their price objective on shares of Medpace from $525.00 to $500.00 and set an “underweight” rating on the stock in a research report on Wednesday, February 11th. Truist Financial decreased their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a report on Wednesday, February 11th. Royal Bank Of Canada assumed coverage on shares of Medpace in a research note on Tuesday. They issued an “outperform” rating and a $522.00 target price on the stock. Finally, TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and reduced their price target for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Five analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Medpace has a consensus rating of “Hold” and an average target price of $486.67.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.